While routine blood testing is not cost effective for Stage I–III melanoma, newer serum markers for melanoma have been proposed, including melanoma inhibitory activity (MIA), tyrosinase, 5-S-cysteinyldopa and serum protein S-100B [101]. This evidence concerns the gene TYR and melanoma.